Literature DB >> 28950072

STAT1 in cancer: friend or foe?

Ying Zhang1,2, Zhaoyong Liu3,2.   

Abstract

The first STAT family member, STAT1, is an essential component of interferon (IFN)-signaling, which mediates several cellular functions in response to stimulation by cytokines, growth factors, and hormones, such as the IFNs and IL-6. The role and significance of STAT1 in cancer biology have been studied for a decade. The majority of evidence shows that activating STAT1 plays a tumor suppressor role in cancer cells. Nevertheless, results from some experiments and clinical studies suggest that STAT1 also exerts tumor promoter effects under specific conditions. In some malignant phenotypes, STAT1 can function either as an oncoprotein or tumor suppressor in the same cell type, depending on the specific genetic background. Thus, the function of STAT1 in cancer biology remains a mystery. In this review, we discuss both the "friend" and "foe" features of STAT1 by summarizing its tumor suppressor or oncogenic functions and mechanisms. To explain how STAT1 may mediate its tumor suppressor effects, we discuss several possible mechanisms, one of which is linked to the role of STAT1β, an isoform of STAT1.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28950072

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  32 in total

1.  Integrative analysis of differential circular RNA and long non-coding RNA profiles and associated competing endogenous RNA networks in esophageal squamous cell carcinoma.

Authors:  Jiang-Feng Shen; Jin-Feng Ge; Shi-Ying Zheng; Dong Jiang
Journal:  Funct Integr Genomics       Date:  2021-01-07       Impact factor: 3.410

2.  STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma.

Authors:  Nathan Ryan; Kelvin Anderson; Greta Volpedo; Omar Hamza; Sanjay Varikuti; Abhay R Satoskar; Steve Oghumu
Journal:  Int J Cancer       Date:  2019-11-29       Impact factor: 7.396

3.  The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.

Authors:  Yuan Wei; Qiyi Zhao; Zhiliang Gao; Xiang-Ming Lao; Wei-Ming Lin; Dong-Ping Chen; Ming Mu; Chun-Xiang Huang; Zheng-Yu Liu; Bo Li; Limin Zheng; Dong-Ming Kuang
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

4.  Long Non-coding RNA TPT1-AS1 Suppresses APC Transcription in a STAT1-Dependent Manner to Increase the Stemness of Colorectal Cancer Stem Cells.

Authors:  Bingxue Chen; Haojie Sun; Suting Xu; Qi Mo
Journal:  Mol Biotechnol       Date:  2022-01-12       Impact factor: 2.695

5.  Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors.

Authors:  Toshifumi Tsukahara
Journal:  Clin Transl Oncol       Date:  2022-04-29       Impact factor: 3.340

6.  Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression.

Authors:  Sanjay Chandrasekaran; Maiko Sasaki; Christopher D Scharer; Haydn T Kissick; Dillon G Patterson; Kelly R Magliocca; John T Seykora; Bishu Sapkota; David A Gutman; Lee A Cooper; Gregory B Lesinski; Edmund K Waller; Susan N Thomas; Sergei V Kotenko; Jeremy M Boss; Carlos S Moreno; Robert A Swerlick; Brian P Pollack
Journal:  Mol Cancer Res       Date:  2019-09-23       Impact factor: 5.852

7.  Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.

Authors:  Fangran Liu; Jiao Liu; Jinguo Zhang; Jimin Shi; Lu Gui; Guoxiong Xu
Journal:  Cancer Biol Ther       Date:  2020-10-12       Impact factor: 4.742

8.  circSVIL regulates bovine myoblast development by inhibiting STAT1 phosphorylation.

Authors:  Binglin Yue; Haiyan Yang; Jiyao Wu; Jian Wang; Wenxiu Ru; Jie Cheng; Yongzheng Huang; Xianyong Lan; Chuzhao Lei; Hong Chen
Journal:  Sci China Life Sci       Date:  2021-05-20       Impact factor: 6.038

9.  Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE).

Authors:  Archana Thakur; Sri Vidya Kondadasula; Kyungmin Ji; Dana L Schalk; Edwin Bliemeister; Johnson Ung; Amro Aboukameel; Eli Casarez; Bonnie F Sloane; Lawrence G Lum
Journal:  Cancer Immunol Immunother       Date:  2020-08-31       Impact factor: 6.968

10.  Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy.

Authors:  Shariful Islam; Claudia M Espitia; Daniel O Persky; Jennifer S Carew; Steffan T Nawrocki
Journal:  Blood Adv       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.